This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2024 Feb 1;143(5):380-382.

doi: 10.1182/blood.2023022822.

Old rivals become new friends

Philippe Rousselot¹

Affiliations

PMID: 38300611
DOI: 10.1182/blood.2023022822

Free article

Editorial

Old rivals become new friends

Philippe Rousselot. Blood. 2024.

Free article

. 2024 Feb 1;143(5):380-382.

doi: 10.1182/blood.2023022822.

Author

Philippe Rousselot¹

Affiliation

¹ University of Versailles Paris-Saclay.

PMID: 38300611
DOI: 10.1182/blood.2023022822

No abstract available

PubMed Disclaimer

Comment on

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
Jabbour E, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, Jorgensen J, Wang SA, Alvarado Y, Wang X, DiNardo C, Masarova L, Kadia T, Garris RS, Ravandi F, Kantarjian H. Jabbour E, et al. Blood. 2024 Feb 1;143(5):417-421. doi: 10.1182/blood.2023022330. Blood. 2024. PMID: 37879077 Clinical Trial.

References

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems